Companies Dominating the Pneumonia Testing Landscape
- Abbott
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Quidel Corporation
- Thermo Fisher Scientific Inc.
- bioMérieux SA
- INTEC
- OpGen
- BD (Becton, Dickinson, and Company)
- Meridian Bioscience, Inc.
- Luminex Corporation (DiaSorin S.p.A.)
- F. Hoffmann-La Roche Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of pneumonia testing is evaluated at USD 721.19 million.
The pneumonia testing market size was valued at USD 688.68 million in 2024 and is projected to exceed USD 1.43 billion by the end of 2037, expanding at over 5.9% CAGR during the forecast period i.e., between 2025-2037. Rising cases of COVID-19, Increasing incidence of hospital-acquired pneumonia (HAP), growing geriatric population, and advancement of POCT and nucleic acid detection tests will impel the market growth.
North America is anticipated to hold largest industry share by 2037, fueled by the rising prevalence of pneumonia in the region.
The major players in the market include Abbott, Quidel Corporation, Thermo Fisher Scientific Inc., bioMérieux SA, INTEC, OpGen, BD (Becton, Dickinson, and Company), Meridian Bioscience, Inc., Luminex Corporation (DiaSorin S.p.A.), F. Hoffmann-La Roche Ltd.
